BERGENBIO PRESENTING AT VIRTUAL INVESTOR CONFERENCES
Bergen, Norway, 12[th] January 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that a member of the senior management team is presenting at the following virtual conferences: Solebury Trout Management Access Event, 6-15 January 2021 Register for the event here Presentation available via platform